Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16854083rdf:typepubmed:Citationlld:pubmed
pubmed-article:16854083lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:16854083lifeskim:mentionsumls-concept:C0011923lld:lifeskim
pubmed-article:16854083lifeskim:mentionsumls-concept:C0027930lld:lifeskim
pubmed-article:16854083lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:16854083pubmed:issue15lld:pubmed
pubmed-article:16854083pubmed:dateCreated2006-7-20lld:pubmed
pubmed-article:16854083pubmed:abstractTextA series of Gly-neurotensin(8-13) analogues modified at the N-terminus by acyclic tetraamines (Demotensin 1-4) were obtained by solid-phase peptide synthesis techniques. Strategic replacement of amino acids and/or reduction of sensitive peptide bonds were performed to enhance conjugate resistance against proteolytic enzymes. During 99mTc-labeling, single species radiopeptides, [99mTc]Demotensin 1-4, were easily obtained in high yields and typical specific activities of 1 Ci/micromol. Peptide conjugates displayed a high affinity binding to the human neurotensin subtype 1 receptor (NTS1-R) expressed in colon adenocarcinoma HT-29 or WiDr cells and/or in human tumor sections. [99mTc]Demotensin 1-4 internalized very rapidly in HT-29 or WiDr cells by a NTS1-R-mediated process. [99mTc]Demotensin 3 and 4, which remained stable during 1 h incubation in murine plasma, were selectively studied in nude mice bearing human HT-29 and WiDr xenografts. After injection, [99mTc]Demotensin 3 and 4 effectively and specifically localized in the experimental tumors and were rapidly excreted via the kidneys into the urine, exhibiting overall biodistribution patterns favorable for NTS1-R-targeted tumor imaging in man.lld:pubmed
pubmed-article:16854083pubmed:languageenglld:pubmed
pubmed-article:16854083pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:citationSubsetIMlld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16854083pubmed:statusMEDLINElld:pubmed
pubmed-article:16854083pubmed:monthJullld:pubmed
pubmed-article:16854083pubmed:issn0022-2623lld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:TourwéDirkDlld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:ReubiJean-Cla...lld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:ConrathPeterPlld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:MainaTheodosi...lld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:NikolopoulouA...lld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:NockBerthold...lld:pubmed
pubmed-article:16854083pubmed:authorpubmed-author:MaesVeronique...lld:pubmed
pubmed-article:16854083pubmed:issnTypePrintlld:pubmed
pubmed-article:16854083pubmed:day27lld:pubmed
pubmed-article:16854083pubmed:volume49lld:pubmed
pubmed-article:16854083pubmed:ownerNLMlld:pubmed
pubmed-article:16854083pubmed:authorsCompleteYlld:pubmed
pubmed-article:16854083pubmed:pagination4767-76lld:pubmed
pubmed-article:16854083pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:meshHeadingpubmed-meshheading:16854083...lld:pubmed
pubmed-article:16854083pubmed:year2006lld:pubmed
pubmed-article:16854083pubmed:articleTitleToward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.lld:pubmed
pubmed-article:16854083pubmed:affiliationInstitute of Radioisotopes - Radiodiagnostic Products, National Center for Scientific Research Demokritos, 15310 Athens, Greece.lld:pubmed
pubmed-article:16854083pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16854083pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:16854083pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:16854083lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16854083lld:pubmed